Cryptococcosis

Classification

Cryptococcus is generally classified according to how it is acquired and the site of infection. It typically begins in the lungs before spreading to other parts of the body, particularly the brain and nervous system. Skin involvement is less common.

Signs and symptoms

Cough, shortness of breath, chest pain, and fever are seen when the lungs are infected, resembling pneumonia. There may also be feeling of tiredness. When the brain is infected, symptoms include headache, fever, neck pain, nausea and vomiting, light sensitivity, confusion, or changes in behaviour. It can also affect other parts of the body, including skin, eyes, bones, and prostate. In the skin, it may appear as several fluid-filled nodules with dead tissue. Depending on the site of infection, other features may include loss of vision, blurred vision, inability to move an eye, and memory loss.

Symptom onset is often sudden when lungs are infected and gradual over several weeks when the central nervous system is affected.

Signs and symptoms of cryptococcal infection may be delayed in those with HIV or AIDS. A positive cryptococcal antigen test may precede symptoms by 3 weeks in those with HIV/AIDS. Others may have reactivation of latent cryptococcal disease years later. In those with HIV, approximately 50% of people have a fever, but fever is rare in previously healthy and immunocompetent people with cryptococcosis.

Cause

Cryptococcosis is a common opportunistic infection for AIDS and is particularly common among people living with AIDS in Africa. Other conditions that pose an increased risk include certain malignancies (such as lymphoma), liver cirrhosis, organ transplants, and long-term corticosteroid therapy.

Distribution is worldwide in soil. The prevalence of cryptococcosis has been increasing over the past 50 years for many reasons, including the increase in incidence of AIDS and the expanded use of immunosuppressive drugs.

In humans, C. neoformans chiefly infects the skin, lungs, and central nervous system (causing meningitis). Less commonly, it may affect other organs such as the eye or prostate.

Primary cutaneous cryptococcosis

Primary cutaneous cryptococcosis (PCC) is a distinct clinical diagnosis separate from the secondary cutaneous cryptococcosis that is spread by systemic infection. Males are more likely to develop the infection and a 2020 study showed that the sex bias may be due to a growth hormone, produced by C. neoformans called gibberellic acid (GA) that is upregulated by testosterone. The upper limbs account for a majority of infections. Isolates found in PCC include Cryptococcus neoformans (most common), Cryptococcus gattii, and Cryptococcus laurentii. The prognosis for PCC is generally good outside of disseminated infection.

Morphologic description of the lesions shows umbilicated papules, nodules, and violaceous plaques that can mimic other cutaneous diseases like molluscum contagiosum and Kaposi's sarcoma. These lesions may be present months before other signs of systemic infection in patients with AIDS.

Pulmonary cryptococcosis

Cryptococcus (both C. neoformans and C. gattii) plays a common role in pulmonary invasive mycosis seen in adults with HIV and other immunocompromised conditions. Immune-competent hosts may not seek or require treatment, but careful observation may be important. Cryptococcal pneumonia has the potential to disseminate to the central nervous system (CNS), especially in immunocompromised individuals.

Pulmonary cryptococcosis has a worldwide distribution and is commonly underdiagnosed due to limitations in diagnostic capabilities. Since pulmonary nodules are its most common radiological feature, they can clinically and radiologically mimic lung cancer, TB, and other pulmonary mycoses. The sensitivity of cultures and the Cryptococcal (CrAg) antigen with a lateral flow device on serum is rarely positive in the absence of disseminated disease. Moreover, pulmonary cryptococcosis worsens the prognosis of cryptococcal meningitis.

Cryptococcal meningitis

Cryptococcal meningitis (infection of the meninges, the tissue covering the brain) is believed to result from the dissemination of the fungus from either an observed or undetected pulmonary infection. Often, there is also silent dissemination throughout the brain when meningitis is present. People with defects in their cell-mediated immunity, for example, people with AIDS, are especially susceptible to disseminated cryptococcosis. Cryptococcosis is often fatal, even if treated. It is estimated that the three-month case-fatality rate is 9% in high-income regions, 55% in low/middle-income regions, and 70% in sub-Saharan Africa. As of 2009 there were globally approximately 958,000 annual cases and 625,000 deaths within three months after infection.

Although C. neoformans infection most commonly occurs as an opportunistic infection in immunocompromised people (such as those living with AIDS), C. gattii often infects immunocompetent people as well.

Cryptococcus species (both C. neoformans and C. gattii) are responsible for 68% of meningitis cases in those with HIV. Cryptococcus is considered an "emerging" disease in healthy adults. Though the rate of infection is clearly higher with immunocompromised individuals, some studies suggest a higher mortality rate in patients with non-HIV cryptococcal meningitis secondary to the role of T-cell mediated reaction and injury. CD4+ T cells have proven roles in the defense against Cryptococcus, but it can also contribute to clinical deterioration due its inflammatory response.

Diagnosis

Symptom onset is often subacute, progressively worsens over several weeks, and delays in diagnosis are associated with increased mortality.

Cerebrospinal fluid (CSF) or blood antigen testing by lateral flow assay for cryptococcal antigens has a sensitivity and specificity greater than 99% for cryptococcosis. A CSF fungal culture can tell if there is a microbiological failure (failure of the fungal infections to treat the infection). CSF fungal culture has a 90% sensitivity and 100% specificity for the diagnosis of cryptococcal meningitis. CSF cell analysis is characterized by increased lymphocytes, reduced protein, and reduced glucose. For any person who has cryptococcosis at a site outside of the central nervous system (e.g., pulmonary cryptococcosis), a lumbar puncture is indicated to evaluate the cerebrospinal fluid (CSF) for evidence of cryptococcal meningitis, even if they do not have signs or symptoms of CNS disease. Detection of cryptococcal antigen (capsular material) by culture of CSF, sputum, and urine provides a definitive diagnosis. although the sensitivity is poor in early infection, and may miss 15–20% of patients with culture-positive cryptococcal meningitis. Rapid diagnostic methods to detect cryptococcal antigen include latex agglutination testing, lateral flow immunochromatographic assay (LFA), or enzyme immunoassay (EIA). Polymerase chain reaction (PCR) has been used on tissue specimens, with PCR having a sensitivity of 82% and a specificity of 98% for cryptococcal infection.

Image:Cryptococcosis of lung in patient with AIDS. Mucicarmine stain 962 lores.jpg Image:Pulmonary cryptococcosis (1) histiocytic penumonia.jpg Image:Pulmonary cryptococcosis (3) Alcian blue-PAS.jpg Image:Cryptococcus smear MGG 2010-01-26.JPG Image:Cryptococcus smear MGG 2010-01-27.JPG Image:Cryptococcus smear PAS 2010-01-26.JPG

Prevention

Cryptococcosis is a very subacute infection with a prolonged subclinical phase lasting weeks to months in persons with HIV/AIDS before the onset of symptomatic meningitis. In Sub-Saharan Africa, the prevalence rate of detectable cryptococcal antigen in peripheral blood is often 4–12% in persons with CD4 counts lower than 100 cells/mcL. Cryptococcal antigen screen and preemptive treatment with fluconazole are cost-saving to the healthcare system by avoiding cryptococcal meningitis. The World Health Organization recommends cryptococcal antigen screening in HIV-infected persons entering care with CD4

Antifungal prophylaxis such as fluconazole and itraconazole reduces the risk of contracting cryptococcosis in those with low CD4 cell count and high risk of developing such disease in a setting of cryptococcal antigen screening tests are not available.

Treatment

Treatment options for persons without HIV infection have not been well studied. Intravenous amphotericin B combined with flucytosine by mouth is recommended for initial treatment (induction therapy).

People living with AIDS often have a greater burden of disease and higher mortality (30–70% at 10 weeks). Recommended therapy is with amphotericin B and flucytosine. Adding flucytosine to amphotericin* B is associated with earlier fungal clearance and increased survival; however, it is not readily available in many lower-income regions. Where flucytosine is not available, fluconazole should be used with amphotericin. Amphotericin-based induction therapy has much greater microbiologic activity than fluconazole monotherapy with 30% better survival at 10 weeks. Based on a systematic review, the most cost-effective induction treatment in resource-limited settings appears to be one week of amphotericin *B coupled with high-dose fluconazole. After initial induction treatment as above, typical consolidation therapy is with oral fluconazole for at least 8 weeks, used with secondary prophylaxis with fluconazole thereafter.

The decision on when to start treatment for HIV appears to be very different than other opportunistic infections. A large multi-site trial supports deferring ART for 4–6 weeks was overall preferable with 15% better 1-year survival than earlier ART initiation at 1–2 weeks after diagnosis. A 2018 Cochrane review also supports the delayed starting of treatment until cryptococcosis starts improving with antifungal treatment.

Increased intracranial pressure is seen in about 50% of those with HIV-associated cryptococcal meningitis and is usually associated with a high fungal burden. Regular (often daily) lumbar punctures to lower the intracranial pressure by draining CSF is associated with reduced mortality in those with cryptococcal meningitis (with or without HIV). But in those with suspicion of non-communicating hydrocephalus (which may present as focal neurologic symptoms or impaired mentation), a CT or MRI of the brain is required before lumbar puncture to rule out hydrocephalus, due to the risk of brain herniation with lumbar puncture. Non-communicating hydrocephalus is rare in those with HIV-associated cryptococcal meningitis.

IRIS

Immune reconstitution inflammatory syndrome is possible in those with cryptococcal infection, especially those with concurrent HIV starting anti-retroviral therapy. With anti-retroviral therapies for HIV, the CD4+ T-cell counts recover, and the restored immune system mounts an exaggerated, hyperinflammatory response against cryptococcal infection in the body.

IRIS has a 5% incidence in those with HIV and cryptococcosis starting anti-retroviral therapy. It usually occurs within 4 weeks of starting antiretroviral therapy. The risk of IRIS is increased in those with a high fungal burden, lower CD4+ T-cell count, and lower inflammatory marker levels.

Epidemiology

Cryptococcosis is usually associated with immunosuppressed people, such as those with AIDS, corticosteroid use, diabetes, and organ transplant. Cryptococcus comprizes two clinically relevant species, Cryptococcus neoformans and Cryptococcus gattii. C. gattii was previously thought to only be found in tropical climates and in immunocompetent persons, but recent findings of C. gattii in regions such as Canada and Western regions of North America have challenged this initial presumption of the geographic patterns.

Data from 2009 estimated that of the almost one million cases of cryptococcal meningitis that occurred worldwide annually, 700,000 occurred in sub-Saharan Africa and 600,000 per year died. In 2014, amongst people who had a low CD4+ cell count, the annual incidence rate was estimated to be 278,000 cases. Of those, 223,100 resulted in cryptococcal meningitis. About 73% of cryptococcal meningitis cases occurred in Sub-Saharan Africa. More than 180,000 fatalities are attributed to cryptococcal meningitis, 135,000 of which occur in sub-Saharan Africa. Case fatality of cryptococcal meningitis varies widely depending on the country where the infection occurs. In low-income countries, the case fatality from cryptococcal meningitis is 70%. This differs from middle-income countries, where the case fatality rate is 40%. In wealthy countries, the case fatality is 20%. 19% of all AIDS-related deaths are due to cryptococcal disease. Cryptococcal disease is the second leading cause of death in those with HIV/AIDS, second only to tuberculosis, which is responsible for 40% of deaths. In sub-Saharan Africa, approximately a third of HIV patients will develop cryptococcosis.

In the United States

In the United States, the incidence of cryptococcosis is estimated to be about 0.4–1.3 cases per 100,000 population and 2–7 cases per 100,000 in people affected with AIDS, with a case fatality ratio of about 12%. Since 1990, the incidence of AIDS-associated cryptococcosis has fallen by 90% due to the proliferation of antiretroviral therapy. The estimated prevalence of cryptococcosis cases amongst HIV patients in the U.S. is 2.8%. In immunocompetent patients, cryptococcus typically presents itself as Cryptococcus gattii. Despite its rarity, cryptococcus has been more commonly seen, with upwards of 20% of cases in immunocompetent people. Over 50% of cryptococcosis infections in North America are caused by C. gattii. Though C. gattii was originally thought to be restricted to subtropical and tropical regions it has become more prevalent worldwide. C. gattii has been found in over 90 people in the United States, most of these cases originating in Washington or Oregon.

In sub-Saharan Africa

Sub-Saharan Africa is the main hub for HIV/AIDS worldwide. HIV/AIDS accounts for about 0.5% of the world's population. Remarkably, sub-Saharan Africa holds 71% of HIV/AIDs cases. Cryptococcal meningitis is a primary contributor to mortality among individuals with HIV/AIDS in sub-Saharan Africa. Approximately 160,000 cases of cryptococcal meningitis are reported in West Africa, resulting in 130,000 deaths in sub-Saharan Africa. Uganda is reported to have the highest occurrence of cryptococcus meningitis. Reflecting that, Ethiopia has the least occurrence. Presently, treatment options involve either a 7 or 14-day regimen of amphotericin-B, coupled with oral antifungal tablets or oral fluconazole. It is important to note that amphotericin B is not considered a treatment, as it showed no significant reduction in the mortality rate.

Other animals

Cryptococcosis is also seen in cats and occasionally in dogs. It is the most common deep fungal disease in cats, usually leading to chronic infection of the nose and sinuses and skin ulcers. Cats may develop a bump over the bridge of the nose from local tissue inflammation. It can be associated with FeLV infection in cats. Cryptococcosis is most common in dogs and cats, but cattle, sheep, goats, horses, wild animals, and birds can also be infected. Soil, fowl manure, and pigeon droppings are among the sources of infection.

References

References

1. "Cryptococcosis".
2. (29 December 2020). "C. neoformans Infection". Centers for Disease Control and Prevention.
3. (29 January 2021). "Where C. gattii Infection Comes From". Centers for Disease Control and Prevention.
4. (14 January 2021). "Treatment for C. neoformans Infection". Centers for Disease Control and Prevention.
5. "ICD-11 — ICD-11 for Mortality and Morbidity Statistics".
6. (March 2016). "Cryptococcosis". Infectious Disease Clinics of North America.
7. (January 2025). "Reframing the clinical phenotype and management of cryptococcal meningitis". Practical Neurology.
8. (14 January 2021). "Symptoms of C. neoformans Infection". Centers for Disease Control and Prevention.
9. (2017). "Weedon's Skin Pathology Essentials". Elsevier.
10. (2 February 2021). "Where C. neoformans Infection Comes From". Centers for Disease Control and Prevention.
11. (November 2012). "Mechanisms of infection by the human fungal pathogen Cryptococcus neoformans". Future Microbiology.
12. (2016). "Fungal Infections, An Issue of Infectious Disease Clinics of North America". Elsevier.
13. (July 2022). "Elevated Intracranial Pressure in Cryptococcal Meningoencephalitis: Examining Old, New, and Promising Drug Therapies". Pathogens.
14. (February 2019). "Pulmonary cryptococcosis: A review of pathobiology and clinical aspects". Medical Mycology.
15. (September 2010). "Meningitis: cryptococcal: Overview". University of Maryland Medical Center.
16. (June 2021). "Cryptococcosis". Infectious Disease Clinics of North America.
17. (2020). "The Role of Testosterone and Gibberellic Acid in the Melanization of Cryptococcus neoformans". Frontiers in Microbiology.
18. (August 2015). "Systemic Review of Published Reports on Primary Cutaneous Cryptococcosis in Immunocompetent Patients". Mycopathologia.
19. (May 1996). "Cutaneous Cryptococcus infection and AIDS. Report of 12 cases and review of the literature". Archives of Dermatology.
20. (May 2011). "Treatment of asymptomatic pulmonary cryptococcosis in immunocompetent hosts with oral fluconazole". Scandinavian Journal of Infectious Diseases.
21. (April 2000). "Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America". Clinical Infectious Diseases.
22. (December 2011). "Pulmonary cryptococcosis". Seminars in Respiratory and Critical Care Medicine.
23. (February 2009). "Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS". AIDS.
24. (2011-02-08). "Genome variation in Cryptococcus gattii, an emerging pathogen of immunocompetent hosts". American Society for Microbiology.
25. (May 2024). "Cryptococcal Disease in Diverse Hosts". The New England Journal of Medicine.
26. (March 2018). "Long-term Mortality and Disability in Cryptococcal Meningitis: A Systematic Literature Review". Clinical Infectious Diseases.
27. (September 2019). "Clinical Aspects of Immune Damage in Cryptococcosis". Current Fungal Infection Reports.
28. (November 2017). "CD4⁺ T Cells Orchestrate Lethal Immune Pathology despite Fungal Clearance during Cryptococcus neoformans Meningoencephalitis". mBio.
29. (September 1996). "Modified India ink preparation for Cryptococcus neoformans in cerebrospinal fluid specimens". Journal of Clinical Microbiology.
30. (January 2014). "Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast". Emerging Infectious Diseases.
31. "FIGURE 1. Prevalence of asymptomatic antigenemia with corresponding cost per life saved based on LFA cost of $2.50 per test.".
32. (August 2010). "Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings". Clinical Infectious Diseases.
33. (April 2012). "Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care". Journal of Acquired Immune Deficiency Syndromes.
34. (April 2011). "Routine cryptococcal antigen screening for HIV-infected patients with low CD4+ T-lymphocyte counts--time to implement in South Africa?". South African Medical Journal = Suid-Afrikaanse Tydskrif vir Geneeskunde.
35. (December 2012). "Reconsidering cryptococcal antigen screening in the U.S. among persons with CD4 <100 cells/mcL". Clinical Infectious Diseases.
36. (July 2014). "Prevalence and correlates of cryptococcal antigen positivity among AIDS patients--United States, 1986-2012". MMWR. Morbidity and Mortality Weekly Report.
37. (August 2018). "Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people". The Cochrane Database of Systematic Reviews.
38. (2010). "Practice Guidelines for the Management of Cryptococcal Disease". Infectious Disease Society of America.
39. World Health Organization. "Rapid advice: Diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents, and children".
40. (2012). "Prognosis and management of cryptococcal meningitis in patients with HIV infection". Neurobehavioral HIV Medicine.
41. (2012). "Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis". PLOS Medicine.
42. (June 2014). "Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis". The New England Journal of Medicine.
43. (July 2018). "Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis". The Cochrane Database of Systematic Reviews.
44. (December 2014). "The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis". Clinical Infectious Diseases.
45. (February 2010). "Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america". Clinical Infectious Diseases.
46. (2023). "StatPearls". StatPearls Publishing.
47. (September 2010). "Prevalence of the VNIc genotype of Cryptococcus neoformans in non-HIV-associated cryptococcosis in the Republic of Korea". FEMS Yeast Research.
48. (February 2012). "Cryptococcus gattii: where do we go from here?". Medical Mycology.
49. (August 2017). "Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis". The Lancet. Infectious Diseases.
50. (December 2022). "The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis". The Lancet. Infectious Diseases.
51. (July 2024). "HIV-Associated Tuberculosis". The New England Journal of Medicine.
52. (2022-11-02). "C. neoformans Infection Statistics". Centers for Disease Control and Prevention.
53. (March 2020). "Magnitude of Cryptococcosis among HIV patients in sub-Saharan Africa countries: a systematic review and meta-analysis". African Health Sciences.
54. (August 2023). "Cryptococcal Meningitis in Young, Immunocompetent Patients: A Single-Center Retrospective Case Series and Review of the Literature". Open Forum Infectious Diseases.
55. (October 2022). "Pulmonary Cryptococcosis". Journal of Fungi.
56. (February 2012). "Cryptococcus gattii: where do we go from here?". Medical Mycology.
57. "HIV and AIDS Epidemic Global Statistics".
58. (2016-04-08). "HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities". The Open AIDS Journal.
59. (2022-11-02). "C. neoformans Infection Statistics". Centers for Disease Control and Prevention.
60. (January 2021). "Epidemiology of Cryptococcus and cryptococcosis in Western Africa". Mycoses.
61. (March 2020). "Magnitude of Cryptococcosis among HIV patients in sub-Saharan Africa countries: a systematic review and meta-analysis". African Health Sciences.
62. (November 2018). "High Mortality in HIV-Associated Cryptococcal Meningitis Patients Treated With Amphotericin B-Based Therapy Under Routine Care Conditions in Africa". Open Forum Infectious Diseases.
63. "Deep Fungal Infections".
64. (July 2014). "Feline Cryptococcosis – WSAVA 2003 Congress – VIN".